Loading
Domvanalimab is an experimental monoclonal antibody from Gilead Sciences in phase 3 trials for non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.
Domvanalimab (AB154, GS-0154) is a monoclonal antibody developed by Gilead Sciences and Arcus Biosciences. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 7 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05211895 (A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC) and NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer), in non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma. The largest, NCT05502237, plans to enrol 1021 participants (actual) with primary completion expected 2028-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Domvanalimab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Domvanalimab" OR ABSTRACT:"Domvanalimab" OR TITLE:"AB154" OR ABSTRACT:"AB154" OR TITLE:"GS-0154" OR ABSTRACT:"GS-0154") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Domvanalimab, not a curated reading list.
Shares A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies, Study With Various Immunotherapy Treatments in Participants With Lung Cancer, Arcus Biosciences, Gilead Sciences (incl. Kite) and the tag pipeline.
Shares A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies, Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst, Study With Various Immunotherapy Treatments in Participants With Lung Cancer, Study of Novel Treatment Combinations in Patients With Lung Cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Non-small-cell lung cancer and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Bladder & urothelial cancer and the tag pipeline.